2025³â 08¿ù 07ÀÏ ¸ñ¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > Àαⴺ½º

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
 
¸ðµÎ 92542°³ÀÇ ´º½º°¡ °Ë»öµÇ¾ú½À´Ï´Ù.



ÅÂÇ×È£, MBC ¡®¸Þ¸® ųÁî ÇÇÇᯠÃ⿬

ºÎÇü»ç·Î º¯½Å, Á¶·Â»ç¸Á »ç°Ç ÃßÀû
¹è¿ì ÅÂÇ×È£°¡ Áö³­ 1ÀÏ Ã¹ ¹æ¼ÛµÈ MBC ±ÝÅäµå¶ó¸¶ ‘¸Þ¸® ųÁî ÇÇÇÃ’(±âȹ ±Ç¼ºÃ¢ / ¿¬Ãâ ¹ÚÁØ¿ì / ±Øº» À̼ö¾Æ / Á¦ÀÛ ¹Ì½ºÅͷθǽº, ¹«ºùÇÈÃĽºÄÄÆÛ´Ï, ½ºÆ©µð¿À ¾ÈÀÚÀÏ·»)À» ÅëÇØ ½ÃûÀÚµé°ú ¸¸³µ´Ù.   ‘¸Þ¸® ųÁî ÇÇÇÃ’Àº Ä¡·á°¡ ºÒ°¡´ÉÇÑ È¯ÀÚµéÀÇ Á¶·Â »ç¸ÁÀ» µ½´Â ÀÇ»ç¿Í À̸¦ ÃßÀûÇÏ´Â Çü»çÀÇ À̾߱⸦ ±×¸° ¼­½ºÆæ½º µå¶ó¸¶´Ù.   ±Ø Áß ÅÂÇ×È£´Â ±¤¼ö´ëÀå żº(±èÅÂ¿ì ºÐ)°ú ÇÔ²² »ç°ÇÀ» ÂÑ´Â ‘ºÎÇü»ç’·Î ºÐÇØ, Á¶·Â »ç¸Á »ç°ÇÀÇ ½Çü¿¡ ´Ù°¡¼­±â À§ÇØ ÇöÀåÀ» ´©ºñ°í ´Ü¼­¸¦ ...

KGM, Áö´ÉÇüÀÚµ¿Â÷ºÎǰÁøÈï¿ø°ú ÀÚÀ²ÁÖÇà ±â¼úÇù·Â MOU

ÀÚÀ²ÁÖÇà °ü·Ã À¯·´ ¹ý±Ô ´ëÀÀÀº ¹°·Ð ¾ç»ê ±â¼ú È®º¸ ±â´ë
KG ¸ðºô¸®Æ¼(ÀÌÇÏ KGM)°¡ Áö´ÉÇüÀÚµ¿Â÷ºÎǰÁøÈï¿ø (ÀÌÇÏ ÁøÈï¿ø)°ú ÀÚÀ²ÁÖÇà ±â¼ú °³¹ß MOU¸¦ ü°áÇÏ°í »óÈ£Çù·ÂÇϱâ·Î Çß´Ù. Áö³­ 28ÀÏ(¿ù) ÁøÈï¿ø º»»ç(´ë±¸½Ã ´Þ¼º±º ¼ÒÀç)¿¡¼­ ¿­¸° MOU ü°á½Ä¿¡´Â KGM ±Ç¿ëÀÏ ±â¼ú¿¬±¸¼Ò ¼ÒÀå°ú ÁøÈï¿ø ¼­ÀçÇü ¿øÀåÀ» ºñ·ÔÇÑ °ü°èÀÚµéÀÌ Âü¼®Çß´Ù. ÁøÈï¿øÀº ÀÚÀ²ÁÖÇàÂ÷ µî Â÷¼¼´ë ÀÚµ¿Â÷ ±â¼úÀ» °³¹ßÇÏ´Â °ü·Ã ¾÷ü¿Í ¿¬±¸±â°üÀ» Áö¿øÇϱâ À§ÇØ 2014³â ¼³¸³µÈ ½ÃÇè Àü¹® ±â°üÀ¸·Î, °í¼Ó ÁÖȸ·Î, ¹ü¿ë ½ÃÇè·Î µî ´Ù¾çÇÑ Á¶°Ç¿¡¼­ÀÇ ÀÚµ¿Â÷ ÁÖÇà ½ÃÇè ¹× Ãæ°Ý ³»±¸ ½ÃÇè Àåºñ µîÀÇ ½Ã¼³ ¹× ½ÃÇè Àη ...

Novotech Report: How In-Vivo CAR-T May Reshape Cell Therapy Econo...
SYDNEY -- With in-vivo CAR-T therapies gaining global momentum, a new whitepaper from Novotech, a leading global full-service clinical Contract Research Organization (CRO) and scientific advisory company, offers insight into this next frontier of immunotherapy. In-Vivo CAR Therapies - Global Research and Development Landscape (2025) report explores the accelerating innovation in in-vivo CAR-T (Chimeric Antigen Receptor) technologies and their potential to reshape treatment across oncology, autoi ...
GS25, Áï¼® ÄÅ¹ä ¸ÅÃâ 36.1% ½ÅÀ塦 Àüü ¸ÅÃâ °ßÀÎ (2020-06-15)
¾ÈÀüÇÑ ¸¶ÄÏ, ¼º°ø¸®¿¡ °³ÃֵŠ(2020-06-15)
À¯¿ë½Å ÀÛ°¡ ¿Àµð¿ÀºÏ ¡®¿À´Ã ÇູÇϰڽÀ´Ï´Ù¡¯ (2023-02-17)
ÀÌ»óÀ±, 'ÈÆÈÆÇÑ ³²Ä£·è' °øÇ×ÆÐ¼ÇÀ¸·Î ½Ã¼± ÁýÁß (2015-12-01)
Çѱ¹±³Á÷¿ø°øÁ¦È¸, ȯ°æÆË¾÷¸¶ÄÏ °³ÃÖ (2023-06-08)
°øÁø¿ø ´Ü¿À¸ÂÀÌ Çà»ç ¡®½Ã½Ã¶§¶§ ¼¼½Ãdz¼Ó¡¯ (2023-07-15)
GS25, ¡®°«»ý±âȹÅÛ¡¯ ÇÑ ´Þ°£ 200¸¸ °³ ÆÇ¸Å (2021-10-09)
ÀºÇà±Ç °¨»ç, ´ëºÎºÐ ³«ÇÏ»ê Ÿ°í ±Þ¿©´Â ÃÖ°í (2018-10-02)
5G ´ë¿ªÆø ¼±ÅÃÀ¸·Î 5650¾ï´Þ·¯ ±Û·Î¹ú GDP âÃâ (2018-12-15)
·ç¾Ç¿Àµð¿À, ½ÅÁ¦Ç° R3 Ãâ½Ã (2020-10-26)
°ÔÀÓ ¸ôÀÔ°¨ ³ôÀÌ´Â Àα⠼º¿ìµéÀÇ È°¾à (2016-06-10)
´ºÆ®·Î Ç»Àü¼úÁý, ½Å°£ÀÌ¿ª ÀÎõÇÐÀÍÁ¡ ¿ÀÇ (2019-11-13)
¾àÀç·Î ÆÈ¸®´Â õ¿¬±â³ä¹° ³²»ýÀÌ ±¸Á¶ (2021-04-29)
»ï¼ºSDS, ½±°Ô Ȱ¿ë °¡´ÉÇÑ ºí·ÏüÀÎ ¼­ºñ½º (2021-07-12)
MBN ¡®¿ì¸® ´Ù½Ã »ç¶ûÇÒ ¼ö ÀÖÀ»±î2¡¯ ù ´ÜÇÕ´ëȸ (2020-05-16)
Áö¿ª Áß¼Ò»ó°øÀο¡ ¼³³¯ Ưº°ÀÚ±Ý 1Á¶6000¾ï¿ø Áö¿ø (2022-12-27)
Çѱ¹ ´ëÇ¥±×·ìÀº ¡®»ï¼º¡¯, ´ëÇ¥»ê¾÷Àº ¡®ITÀÎÅͳݡ¯ (2020-06-22)
±¹¼¼Ã», ¹Î»ýÄ§ÇØ Å»¼¼ÀÚ Á¶»ç Âø¼ö (2014-04-17)
½ÅÇѱÝÀ¶±×·ì, º£Æ®³² Ǫ¸£µ§¼È¼ÒºñÀÚ±ÝÀ¶ Àμö (2018-01-23)
±³Åëºòµ¥ÀÌÅÍ ¿¬°è ¼­ºñ½º ÃßÁø MOU (2020-11-17)
Çö¹Ì¹ä Àü¿ë ¸ã½Ò ¡®º¸µå¶ó¹Ì¡¯ °³¹ß (2014-11-10)
Á÷ÀåÀÎ 16.9%, ¾Ë¹Ù... ¼öÀÔ ¿ùÆò±Õ 37¸¸6õ¿ø (2020-03-25)
Çö´ë·ÎÅÛ, È£ÁÖ ½Ãµå´Ï 2Ãþ Àüµ¿Â÷ 42·® ¼öÁÖ (2019-03-06)
GSÇÁ·¹½Ã¸ô, Ãʰ³ÀÎÈ­ Å¥·¹ÀÌ¼Ç ¼­ºñ½º (2022-06-10)
¡®µµ¼­¡¤°ø¿¬ºñ ¼Òµæ°øÁ¦¡¯ Á¦µµ ½ÃÇà ÈÄ µµ¼­ ¸ÅÃâ Áõ°¡ (2018-07-12)
       [ÀÌÀü][1]....[2246][2247][2248][2249][2250][2251][2252][2253][2254]...[3702][´ÙÀ½]

°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ
 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..